Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONNEX-X long-term safety extension study of once-daily Iclepertin in schizophrenia
2024-511560-93-00Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2024
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 40
01
Overview
Phase 3, open-label, single-arm trial of iclepertin in schizophrenia, sponsored by Boehringer Ingelheim. Primary endpoint: Treatment-emergent adverse events. Started Jun 2024; status: completed.
02
Drugs
iclepertin
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2024-511560-93-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511560-93-00.